B2G Life Sciences
  • HOME
  • CONSULTING
  • CLINICAL RESEARCH
  • WE'RE EXPERTS
  • THE TEAM
    • OUR VISION
    • NEW OPPORTUNITIES
  • Blog
  • LET'S TALK
  • HOME
  • CONSULTING
  • CLINICAL RESEARCH
  • WE'RE EXPERTS
  • THE TEAM
    • OUR VISION
    • NEW OPPORTUNITIES
  • Blog
  • LET'S TALK
Search by typing & pressing enter

YOUR CART

Clinical Development & Medical Affairs.

19/1/2021 0 Comments

Medical Affairs: Back to Basics

In the setting of increasing challenges for the Pharma industry, medical affairs teams have wide opportunities to take the lead to improve their companies’ positions for a quality drug development, while better addressing needs from patient, physicians, regulators and stakeholders.
 
Tips to make medical affairs on the top could be summarized to the following:
 
  • Deeply know the product and understand the disease 
  • Excel at communicating scientific evidence
  • Link scientific and clinical results to patient outcomes (and do not only focus on product)
  • Build long-term relationships with a variety of stakeholders (HCP, payers, patients, KOL, providers) allowing a better understanding of the market and patient needs
  • Actively participate to development strategy of new drugs by providing market-based input on unmet medical needs and clinical requirements
  • Develop a strategy for market education on a newly launched product
  • Design and implement data generation strategies
 
To do so effectively, medical value teams need to be an integral part of cross-functional product development and product management teams. By working with all pharma functions, they can help increase the company’s understanding of unmet medical needs, and attractiveness of treatment pathways, thus valuating clinical trial protocols options, speeding regulatory approvals and increasing launch success rates.
0 Comments

19/1/2021 0 Comments

Pilar Role of Medical Affairs

Never before have Pharma companies developed data and scientific insights. But information channels are changing, and many companies have difficulty communicating science effectively with the growing array of stakeholders that influence purchasing decisions.

Equipped with deep product knowledge and disease understanding, medical affairs teams can become a strategic ace in an era of Big Data. They are well positioned to generate and present high-quality scientific knowledge to the market and educate stakeholders about next-generation products.

In one hand, a huge amount of data is flooding the market, leaving physicians, payers and healthcare providers struggling with data overload. On the other hand, physicians are reducing their reliance on sales representatives and are keener to seek scientific sources of information. Medical affairs have to be that bridge between stakeholders and pharmaceutical companies. 

An experienced medical affairs team can link scientific and clinical results to patient outcomes, adding value at every stage of a drug’s development. When discussing a potential new compound with physicians, payers and opinion leaders, for instance, medical affairs teams gather vital feedback on the drug’s market potential and patient needs at the earliest stages of the drug development process. The insights they glean over time can improve return on investment and create a strong competitive advantage by helping companies design more effective clinical programs and launches.
​
The winners in an era of Big Data will transform medical affairs teams into medical value teams with three strategic roles: communicating scientific evidence, providing market-based strategic input to drug development and portfolio management, and overseeing the effort to produce Big Data and real-world evidence.


 

0 Comments

    Author

    B2G Life Sciences Team

    View my profile on LinkedIn

    RSS Feed

© 2021. All Rights Reserved